Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avadel Pharmaceuticals Plc (NQ: AVDL )

7.720 USD +0.540 (+7.52%)
Streaming Delayed Price Updated: 1:43 PM EST, Jan 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Avadel Pharmaceuticals Plc

< Previous 1 2 3 4 Next >
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
From GlobeNewswire News Releases
Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index
From GlobeNewswire News Releases
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th
From GlobeNewswire News Releases
Thinking about buying stock in Avadel Pharmaceuticals, Nikola Corp, Agile Therapeutics, Biocept Inc, or Uber Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AVDL, NKLA, AGRX, BIOC, and UBER. 
From PR Newswire
Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces FT218 Leadership Transition
From GlobeNewswire News Releases
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy
From GlobeNewswire News Releases
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at BIO Digital
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces Pricing of Public Offering
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with
From GlobeNewswire News Releases
Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Topline data from the REST-ON study expected in Q2 2020 
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
From GlobeNewswire News Releases
LongueVue Capital Adds Experienced Healthcare Operating Partners to Support New & Existing Investments
LongueVue Capital Partners ("LVC"), a partnership-driven, operator-centric private equity firm based in New Orleans with approximately $500 million of assets under management, announced today that... 
From PR Newswire
Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
From GlobeNewswire News Releases
Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)
USPTO issues Orange Book-listed patent for Nouress 
From GlobeNewswire News Releases
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.